Amedeo Smart

Free Medical Literature Service

 

Amedeo

Arrhythmias
  Free Subscription

Articles published in
J Cardiovasc Pharmacol
    November 2024
  1. SCHULZ C, Eschenhagen T, Christ T
    Atrial hiPSC-CM as a Pharmacologic Model to Evaluate Anti-AF Drugs: Some Lessons From I Kur.
    J Cardiovasc Pharmacol. 2024;84:479-485.
    >> Share

    October 2024
  2. DAKROUB A, Beaini H, Kibbi R, Moumneh MB, et al
    Comparative Analysis of Anticoagulation Versus Combination Anticoagulation and Antiplatelet Therapy in Atrial Fibrillation Patients Presenting With Gastrointestinal Bleeding.
    J Cardiovasc Pharmacol. 2024 Oct 10. doi: 10.1097/FJC.0000000000001641.
    >> Share

    September 2024
  3. ISMAILI D, Petersen J, Schulz C, Eschenhagen T, et al
    PDE8 Inhibition and Its Impact on ICa,L in Persistent Atrial Fibrillation: Evaluation of PDE8 as a Potential Drug Target.
    J Cardiovasc Pharmacol. 2024 Sep 13. doi: 10.1097/FJC.0000000000001630.
    >> Share

    August 2024
  4. WU L, Li Z, Xu L, Fan Y, et al
    Nrf2 ameliorates atrial fibrosis during antithrombotic therapy for atrial fibrillation by modulating CYP2C9 activity.
    J Cardiovasc Pharmacol. 2024 Aug 12. doi: 10.1097/FJC.0000000000001618.
    >> Share

  5. ZOU Y, Liu X, Hu Y, Zhang C, et al
    Inhibition of alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid Receptors Ameliorates Atrial Inflammation and Vulnerability to Atrial Fibrillation in Rats with Anxiety Disorders.
    J Cardiovasc Pharmacol. 2024;84:227-238.
    >> Share

  6. GOLINO M, Lazzerini PE
    Hydroxychloroquine, Chloroquine, and Arrhythmic Risk in Systemic Autoimmune Diseases: Focus More on the Patient and You Will Keep the Rhythm!
    J Cardiovasc Pharmacol. 2024;84:149-151.
    >> Share

  7. NIKOLIC RPA, Virk MK, Buhler KA, Costenbader KH, et al
    Hydroxychloroquine and Chloroquine-Induced Cardiac Arrhythmias and Sudden Cardiac Death in Patients With Systemic Autoimmune Rheumatic Diseases: A Systematic Review and Meta-Analysis.
    J Cardiovasc Pharmacol. 2024;84:158-169.
    >> Share

    July 2024
  8. BURASHNIKOV A, Antzelevitch C
    The efficacy of INa block to cardiovert atrial fibrillation is enhanced by inhibition of IK1.
    J Cardiovasc Pharmacol. 2024 Jul 29. doi: 10.1097/FJC.0000000000001617.
    >> Share

  9. ZHANG J, Xiong X, Li J, Luo C, et al
    Valtrate suppresses TNFSF14-mediated arrhythmia after myocardial ischemia-reperfusion via inducing N-linked glycosylation of LTbetaR to regulate MGA/MAX/c-Myc/Cx43.
    J Cardiovasc Pharmacol. 2024 Jul 19. doi: 10.1097/FJC.0000000000001613.
    >> Share

    March 2024
  10. CHEN YF, Liu NN, Wang JY, Sun JS, et al
    Use of 3D echocardiography facilitates analysis of thrombolytic efficacy in patients with persistent atrial fibrillation.
    J Cardiovasc Pharmacol. 2024 Mar 25. doi: 10.1097/FJC.0000000000001567.
    >> Share

    December 2023
  11. RIVERA FB, Cha SW, Aparece JP, Jariyatamkitti S, et al
    Efficacy and safety of colchicine for the prevention of postoperative atrial fibrillation among patients undergoing major cardiothoracic surgery: a meta-analysis and meta-regression of randomized controlled trials.
    J Cardiovasc Pharmacol. 2023 Dec 28. doi: 10.1097/FJC.0000000000001533.
    >> Share

  12. SPADAFORA L, Gaudio C, Biondi-Zoccai G, Frati G, et al
    Catalysts of cardiovascular electromechanical harmony? Unveiling the impact of RAS Inhibitors and ARNI on atrial fibrillation recurrence after ablation.
    J Cardiovasc Pharmacol. 2023 Dec 27. doi: 10.1097/FJC.0000000000001537.
    >> Share

    November 2023
  13. SUN Q, Cui W, Zhang X, Tian Y, et al
    A Systematic Review and Meta-analysis of Renin-angiotensin Inhibitors and Angiotensin Receptor Neprilysin Inhibitors in Preventing Recurrence after Atrial Fibrillation Ablation.
    J Cardiovasc Pharmacol. 2023 Nov 22. doi: 10.1097/FJC.0000000000001517.
    >> Share

    September 2023
  14. AMARH E, Tisdale JE, Overholser BR
    Prolonged Exposure to Remdesivir Inhibits the Human Ether-A-Go-Go-Related Gene Potassium Current.
    J Cardiovasc Pharmacol. 2023;82:212-220.
    >> Share

    May 2023
  15. AUGUSTIN N, Alvarez C, Kluger J
    The Arrhythmogenicity of Sotalol and its Role in Heart Failure: A Literature Review.
    J Cardiovasc Pharmacol. 2023 May 26. doi: 10.1097/FJC.0000000000001439.
    >> Share

    March 2023
  16. CATURANO A, Brunelli V, Spiezia S, Galiero R, et al
    Optimizing anticoagulation management in atrial fibrillation: beyond the guidelines. How and for whom?
    J Cardiovasc Pharmacol. 2023 Mar 30. doi: 10.1097/FJC.0000000000001423.
    >> Share

    February 2023
  17. PAPAKONSTANTINOU PE, Tsioufis K
    Optimizing anticoagulation management in atrial fibrillation: beyond the guidelines. How and for whom?
    J Cardiovasc Pharmacol. 2023 Feb 14. doi: 10.1097/FJC.0000000000001405.
    >> Share

    November 2022
  18. MOYSIDIS DV, Kartas A, Samaras A, Papazoglou AS, et al
    Prescription rates and prognostic implications of optimally-targeted guideline-directed medical treatment in heart failure and atrial fibrillation Insights from the MISOAC-AF trial.
    J Cardiovasc Pharmacol. 2022 Nov 22. doi: 10.1097/FJC.0000000000001390.
    >> Share

  19. ALEXOPOULOS D, Dragona VM, Varlamos C, Ktenas D, et al
    One-year outcomes in anticoagulated atrial fibrillation patients undergoing percutaneous coronary intervention: insights from the Greek Antiplatelet Atrial Fibrillation (GRAPE-AF) registry.
    J Cardiovasc Pharmacol. 2022 Nov 18. doi: 10.1097/FJC.0000000000001389.
    >> Share

    October 2022
  20. BERNARDI M, Spadafora L, Biondi-Zoccai G
    Should we consider recombinant human brain natriuretic peptide to prevent post-operative atrial fibrillation?
    J Cardiovasc Pharmacol. 2022 Oct 10. pii: 00005344-990000000-00120.
    >> Share

  21. PILOTE S, Simard C, Drolet B
    Remdesivir (VEKLURY) for Treating COVID-19: Guinea Pig Ex Vivo and In Vivo Cardiac Electrophysiological Effects.
    J Cardiovasc Pharmacol. 2022;80:616-622.
    >> Share

  22. ESSA H, Dobson R, Lip GYH
    Chemotherapy-Induced Arrhythmias.
    J Cardiovasc Pharmacol. 2022;80:531-539.
    >> Share

    September 2022
  23. MASTER YW, Master QZ, Master HC, Master ZW, et al
    Effects of recombinant human brain natriuretic peptide on atrial fibrillation after coronary artery bypass grafting.
    J Cardiovasc Pharmacol. 2022 Sep 9. pii: 00005344-990000000-00114.
    >> Share

    August 2022
  24. GAO H, Li Y, Sun H, Huang X, et al
    Trough Concentration Deficiency of Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation Leading to Thromboembolism Events.
    J Cardiovasc Pharmacol. 2022 Aug 23. pii: 00005344-990000000-00103.
    >> Share

  25. CATURANO A, Spiezia S, Brunelli V, Galiero R, et al
    Polypharmacy and major adverse events in atrial fibrillation.
    J Cardiovasc Pharmacol. 2022 Aug 23. pii: 00005344-990000000-00109.
    >> Share

  26. YAN J, Ai X
    Holiday Heart Syndrome, Atrial Fibrillation, and RyR2 antagonist.
    J Cardiovasc Pharmacol. 2022 Aug 10. pii: 00005344-990000000-00092.
    >> Share

  27. GRECO LV, Migirov A, Ojamaa K, Li Y, et al
    Stabilizing Cardiac Ryanodine Receptor with Dantrolene Treatment Prevents Binge Alcohol Enhanced Atrial Fibrillation in Rats.
    J Cardiovasc Pharmacol. 2022 Aug 9. pii: 00005344-990000000-00090.
    >> Share

  28. TUNCTAN B, Senol SP, Temiz-Resitoglu M, Yilmaz DE, et al
    Activation of GPR75 Signaling Pathway Contributes to the Effect of a 20-HETE Mimetic, 5,14-HEDGE, to Prevent Hypotensive and Tachycardic Responses to Lipopolysaccharide in a Rat Model of Septic Shock.
    J Cardiovasc Pharmacol. 2022;80:276-293.
    >> Share

    July 2022
  29. TSAGKARIS C, Papazoglou AS, Kartas A, Samaras A, et al
    Polypharmacy and major adverse events in atrial fibrillation.
    J Cardiovasc Pharmacol. 2022 Jul 29. pii: 00005344-990000000-00089.
    >> Share

    June 2022
  30. HOSSEINI SH, Talasaz AH, Alidoosti M, Tajdini M, et al
    Pre-Procedural Colchicine in Patients with Acute ST-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention: a Randomized Controlled Trial (PodCAST-PCI).
    J Cardiovasc Pharmacol. 2022 Jun 22. pii: 00005344-990000000-00067.
    >> Share

  31. CHEN Y, Zhu M, Wang K, Xu Q, et al
    Direct Oral Anticoagulants Versus Vitamin K Antagonists for the Treatment of Left Ventricular Thrombus: An Updated Meta-Analysis of Cohort Studies and Randomized Controlled Trials.
    J Cardiovasc Pharmacol. 2022;79:935-940.
    >> Share

    May 2022
  32. CARNEVALE R, Biondi-Zoccai G, Giordano A, Pastori D, et al
    From the dining room to the atrium: can we modulate atrial fibrillation risk with micronutrients?
    J Cardiovasc Pharmacol. 2022 May 20. pii: 00005344-990000000-00057.
    >> Share

  33. OLIVERI F, Bongiorno A, Compagnoni S, Fasolino A, et al
    Statin and Post-Cardiac Surgery Atrial Fibrillation Prevention: Systematic Review and Meta-analysis.
    J Cardiovasc Pharmacol. 2022 May 11. pii: 00005344-990000000-00049.
    >> Share

  34. PETERSEN J, Castro L, Bengaard AKP, Pecha S, et al
    Muscarinic Receptor Activation Reduces Force and Arrhythmias in Human Atria Independent of IK,ACh.
    J Cardiovasc Pharmacol. 2022;79:678-686.
    >> Share

    April 2022
  35. RUSSO V, Ammendola E, Gasperetti A, Bottino R, et al
    Add-on Therapy With Sacubitril/Valsartan and Clinical Outcomes in CRT-D Nonresponder Patients.
    J Cardiovasc Pharmacol. 2022;79:472-478.
    >> Share

    March 2022
  36. HUANG J
    Circulating concentrations of nutrition-related factors are not causally associated with atrial fibrillation: a Mendelian randomization study.
    J Cardiovasc Pharmacol. 2022 Mar 25. pii: 00005344-990000000-00012.
    >> Share

    February 2022
  37. LAM JC, Stevenson B, Lee YG, Maurer J, et al
    Intravenous to oral transition of amiodarone (IOTA): effect of various durations of overlap on atrial fibrillation recurrence post cardiothoracic surgery.
    J Cardiovasc Pharmacol. 2022 Feb 11. pii: 00005344-900000000-98047.
    >> Share

    January 2022
  38. ZOU HT, Yang GH, Cai YJ, Chen H, et al
    Are high- or low-dose SGLT2 inhibitors associated with cardiovascular and respiratory adverse events? A meta-analysis.
    J Cardiovasc Pharmacol. 2022 Jan 18. pii: 00005344-900000000-98061.
    >> Share

    December 2021
  39. WANG Z, Wang W, Li H, Zhang A, et al
    Ivabradine and Atrial Fibrillation: A Meta-analysis of Randomized Controlled Trials.
    J Cardiovasc Pharmacol. 2021 Dec 27. pii: 00005344-900000000-98065.
    >> Share

  40. LI W, Chen X, Xie X, Xu M, et al
    Comparison of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide receptor agonists for atrial fibrillation in type 2 diabetes mellitus: systematic review with network meta-analysis of randomised controlled trials.
    J Cardiovasc Pharmacol. 2021 Dec 13. pii: 00005344-900000000-98087.
    >> Share

  41. WANG W, Liu J, Ye H, Wang M, et al
    Effect of Dexmedetomidine on Tachyarrhythmias after Cardiac Surgery: A Systematic Review and Meta-analysis.
    J Cardiovasc Pharmacol. 2021 Dec 13. pii: 00005344-900000000-98086.
    >> Share

    November 2021
  42. ZHENG RJ, Wang Y, Tang JN, Duan JY, et al
    Association of SGLT2 inhibitors with risk of atrial fibrillation and stroke in patients with and without type 2 diabetes: a systemic review and meta-analysis of randomized controlled trials.
    J Cardiovasc Pharmacol. 2021 Nov 22. pii: 00005344-900000000-98109.
    >> Share

  43. BURASHNIKOV A
    Atrial fibrillation induced by anticancer drugs and underling mechanisms.
    J Cardiovasc Pharmacol. 2021 Nov 17. pii: 00005344-900000000-98110.
    >> Share

  44. HIJAZI Y, Karkabi B, Feldman M, Malca B, et al
    Bridging care transition after hospitalization for atrial fibrillation and coronary interventions.
    J Cardiovasc Pharmacol. 2021 Nov 16. pii: 00005344-900000000-98113.
    >> Share

    October 2021
  45. LO CT, Niu F, Fredriks DA, Hui RL, et al
    Evaluation of the effectiveness and safety of Direct Oral Anticoagulants in Elderly Patients with Non-Valvular Atrial Fibrillation who are not Candidates for Warfarin in real world setting.
    J Cardiovasc Pharmacol. 2021 Oct 26. pii: 00005344-900000000-98121.
    >> Share

    August 2021

  46. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Chronic Kidney Disease Stage G4: A Single-Center Experience: Erratum.
    J Cardiovasc Pharmacol. 2021;78:330.
    >> Share

  47. ZHANG M, Wang H, Bie M, Wang X, et al
    Caveolin-1 Deficiency Induces Atrial Fibrosis and Increases Susceptibility to Atrial Fibrillation by the STAT3 Signaling Pathway.
    J Cardiovasc Pharmacol. 2021;78:175-183.
    >> Share

    July 2021
  48. SOLTAN F, Esmaili Dahej M, Yadegari M, Moradi A, et al
    Resveratrol Confers Protection Against Ischemia/Reperfusion Injury by Increase of Angiotensin (1-7) Expression in a Rat Model of Myocardial Hypertrophy.
    J Cardiovasc Pharmacol. 2021;78:e55-e64.
    >> Share

    June 2021
  49. CHARAFEDDINE K, Zakka P, Dargham BB, Abdulhai F, et al
    Potential Biomarkers in Atrial Fibrillation: Insight into their Clinical Significance.
    J Cardiovasc Pharmacol. 2021 Jun 25. pii: 00005344-900000000-98188.
    >> Share

  50. SKORNOVA I, Samos M, Bolek T, Kamenistakova A, et al
    Direct oral anticoagulants plasma levels in atrial fibrillation patients at the time of bleeding: a pilot prospective study.
    J Cardiovasc Pharmacol. 2021 Jun 25. pii: 00005344-900000000-98186.
    >> Share

  51. LOU YM, Zheng ZL, Xie LY, Lian JF, et al
    Effects of spironolactone on hypoxia-inducible factor-1alpha in the patients receiving coronary artery bypass grafting.
    J Cardiovasc Pharmacol. 2021 Jun 25. pii: 00005344-900000000-98182.
    >> Share

    April 2021
  52. TANNER R, Cronin M, Macken L, Murphy R, et al
    Real-World Experience With Antiplatelet Agents After Percutaneous Coronary Intervention in Patients With an Indication for an Oral Anticoagulant.
    J Cardiovasc Pharmacol. 2021;77:501-507.
    >> Share

    March 2021
  53. HEIDEMANN J, Tanislav C, Kostev K
    (Absence of) Association Between Non-Vitamin K Antagonist Oral Anticoagulant Therapy and Urinary Tract Infection in Patients with Atrial Fibrillation.
    J Cardiovasc Pharmacol. 2021 Mar 12. pii: 00005344-900000000-98230.
    >> Share

  54. HORTIGON-VINAGRE MP, Zamora V, Burton FL, Smith GL, et al
    The Use of Voltage Sensitive Dye di-4-ANEPPS and Video-Based Contractility Measurements to Assess Drug Effects on Excitation-Contraction Coupling in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    J Cardiovasc Pharmacol. 2021;77:280-290.
    >> Share

    February 2021
  55. ANOUASSI Z, Atallah B, Alsoud LO, El Nekidy W, et al
    Appropriateness of the Direct Oral Anticoagulants Dosing in the Middle East Gulf Region.
    J Cardiovasc Pharmacol. 2021;77:182-188.
    >> Share

    July 2020
  56. JIA K, Dai Y, Liu A, Li X, et al
    The senolytic agent navitoclax inhibits angiotensin II-induced heart failure in mice Navitoclax inhibits heart failure.
    J Cardiovasc Pharmacol. 2020 Jul 10. doi: 10.1097/FJC.0000000000000878.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016